Volume 2, Issue 1 (2021)
Mary Duguru1, Anejo-okopi Joseph2,3,*, Davwar P Mark1, Omaiye Patientce1, Audu Onyemocho4, Onwuamah Chika5, Okojokwu Julius Ocheme2, Bulus Jonathan6, Chima Anyuku Azubuike George7, Akpa Samuel Tanko2,3, Ramyil M. Selju Crown8, Fiyaktu Bwotle Yakubu9, Agaba Patricia10, Agbaji oche1,3, Sagay Solomon Atiene3,11, Hawkins Claudia12, Okeke N. Edith1
- *Corresponding Author:
- Anejo-okopi Joseph BSC, MBA, MSC, PhD
Department of Microbiology, University of Jos, Main Campus Bauchi Road, Jos, Nigeria.
E-mail: email@example.com, firstname.lastname@example.org
Received date: May 13, 2021; Accepted date: May 24, 2021; Published date: May 31, 2021
Citation: Duguru M, Joseph A, Mark DP, Patientce O, Onyemocho A, Chika O, et al. Liver Fibrosis by Transient Elastography Among HIV/HBV and HBV-Mono Infected Patients on Long-Term Tenofovir Therapy in Jos, Nigeria. J Virol Infect Dis. 2021;2(1):18-25.
Copyright: © 2021 Duguru M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Introduction: Chronic Hepatitis B (CHB) infection both in HIV coinfection and HBV-mono infection are associated with risk of progression to chronic liver disease. Combined tenofovir cART and mono-tenofovir have improved survival in CHB patients. There is paucity of data on Transient Elastography (TE) in HIV/ HBV and HBV-mono infected patients. We aimed to assess liver fibrosis using transient elastography in relation to liver function biomarkers and HBV DNA among HIV/HBV and HBV-mono infected patients on long-term antiviral therapy.
Methods: A cross-sectional study in HBV-HIV and HBV-mono infected adults patients receiving a tenofovir-containing antiretroviral and mono-tenofovir ≥12months at four selected tertiary hospitals in Jos Metropolis from February 2018 to May 2019, after obtained ethical approval from the IRBs and informed consents. The patients’ HBV DNA, platelet count, hematological, biochemical parameters were assessed and liver stiffness measured by TE in kilopascals (kPa), and valid TE measurements were interpreted as: normal (F0-1 0-4), minimal fibrosis (F2 5-7.4), moderate (F3 184.108.40.206), severe fibrosis and cirrhosis (F4 ≥9.5).
Results: A total of 101 (50 HIV/HBV and 51 HBV-mono infected) were enrolled during the study period, comprising of 42.6% males and 57.4% females. The median age interquartile range (IQR); among the HIV/HBV was 40.5(36.0-45.3) and HBV-mono infected 41.0(35.0-49.0). The median Platelet count was low in HBV-mono 195 (168-257), p 0.034. The overall prevalence of severe liver ?brosis (≥ 9.5kPa) was 13/101(13.0%), and among HIV/HBV coinfected and HBV-mono infected patients was 4/50 (8.0%) and 9/51 (17.6%) respectively. The plasma HBV-DNA was <20 copies/mL in 38/50 (76.0%) HIV/HBV and in 30/51(58.8%) HBV-mono patients, 10/50(20.0%) HIV/HBV and 19/50 (37.3%) HBV-mono patients had plasma HBV-DNA of 20-20000 copies/mL. The prevalence of Severe fibrosis (≥ 9.5): in HIV/HBV was 4(8.0%), HBV-mono 9(17.6%). The overall prevalence of thrombocytopenia was 4/101(3.9%): HIV/HBV 1(2.0%) and HBV-mono 3(5.9%).
Liver fibrosis; Transient Elastography; Tenofovir; Chronic Hepatitis B virus; Nigeria